Important Considerations Before Investing in Incyte (INCY)

By Emilio Sanchez • Friday, June 27 10:00 • Permanent Link

Large-cap Health Care company Incyte has logged a -0.2% change today on a trading volume of 107,429. The average volume for the stock is 2,018,170.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Based in Wilmington, United States the company has 2,617 full time employees and a market cap of $13,683,464,192.

The company is now trading -5.93% away from its average analyst target price of $75.15 per share. The 23 analysts following the stock have set target prices ranging from $52.0 to $107.0, and on average give Incyte a rating of buy.

Over the last 52 weeks, INCY stock has risen 16.8%, which amounts to a 4.3% difference compared to the S&P 500. The stock's 52 week high is $83.95 whereas its 52 week low is $53.56 per share. With its net margins declining an average -42.4% over the last 6 years, Incyte may not have a strong enough profitability trend to support its stock price.

Date Reported	Total Revenue ($ k)	Net Profit ($ k)	Net Margins (%)	YoY Growth (%)
2024	4,241,217	32,615	1	-93.75
2023	3,695,649	597,599	16	60.0
2022	3,394,635	340,660	10	-68.75
2021	2,986,267	948,581	32	390.91
2020	2,666,702	-295,697	-11	-152.38
2019	2,158,759	446,906	21

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.